<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00270491</url>
  </required_header>
  <id_info>
    <org_study_id>TAXEL</org_study_id>
    <nct_id>NCT00270491</nct_id>
  </id_info>
  <brief_title>Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.</brief_title>
  <official_title>A Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <brief_summary>
    <textblock>
      Tolerance and efficacy of administration of capecitabine 5 out of 7 days associated with&#xD;
      weekly paclitaxel compared to the recommended treatment plan of weekly paclitaxel -&#xD;
      capecitabine, in patients with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to know if we can optimize in term of tolerance even of efficacy&#xD;
      the plan of administration of weekly paclitaxel associated with capecitabine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tolerance of the patients in the both groups.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Response rates and duration of response.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Haematological and non-haematological toxicities.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Progression free survival.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Overall survival.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Femal patient aged &gt; 18 years&#xD;
&#xD;
          -  Histologically proven breast adenocarcinoma&#xD;
&#xD;
          -  HER2 negative receptors&#xD;
&#xD;
          -  previously received first or second line chemotherapy for metastatic disease&#xD;
&#xD;
          -  previously treated with anthracycline and/or docetaxel in adjuvant and/or as first or&#xD;
             second line therapy&#xD;
&#xD;
          -  presence of one or several evaluable metastatic lesion(s)&#xD;
&#xD;
          -  presence of at least one target lesion not previously irradiated&#xD;
&#xD;
          -  previously treated with hormonotherapy in adjuvant or in metastatic line (treatment&#xD;
             will be ceased upon patient registration in the study)&#xD;
&#xD;
          -  ECOG Performance status &lt; 2&#xD;
&#xD;
          -  adequate biological values&#xD;
&#xD;
          -  patient who has clearly given her consent by signing on informed consent form prior to&#xD;
             participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient previously treated with paclitaxel or capecitabine for metastatic breast&#xD;
             cancer&#xD;
&#xD;
          -  patient with only local metastatic disease (with the exception of axillary lymph&#xD;
             nodes)&#xD;
&#xD;
          -  active symptomatic brain metastasis&#xD;
&#xD;
          -  patient with an history of significant cardiovascular impairment (congestive heart&#xD;
             failure&gt; NYHA grade II, unstable angina or myocardial infraction within the past six&#xD;
             months or serious cardiac arrhythmia)&#xD;
&#xD;
          -  peripheric neuropathy grade ≥ 2&#xD;
&#xD;
          -  history of another malignancy within past 5 years that could confound diagnosis or&#xD;
             staging of breast cancer (with the exception of in situ cacinoma of the cervix or&#xD;
             adequately treated basel cell carcinoma of the skin)&#xD;
&#xD;
          -  patient with any medical or psychiatric condition that, in the opinion of the&#xD;
             Principal Investigator, would preclude her from participating in this study&#xD;
&#xD;
          -  patient with a known allergy to one or several of the study compounds&#xD;
&#xD;
          -  patients who may not be regularly available due to geographical, social or family&#xD;
             reasons&#xD;
&#xD;
          -  history of renal, hepatic or metabolic pathology that could preclude with metabolism&#xD;
             or elimination of the study product&#xD;
&#xD;
          -  deficiencies of the upper intestinal tract, malabsorption syndrome&#xD;
&#xD;
          -  patient who is pregnant, breast-feeding or using inadequate contraception&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rémy LARGILLIER, Physician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre ANTOINE LACASSAGNE - NICE (FRANCE)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital HOTEL DIEU</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>December 26, 2005</study_first_submitted>
  <study_first_submitted_qc>December 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2005</study_first_posted>
  <last_update_submitted>February 24, 2011</last_update_submitted>
  <last_update_submitted_qc>February 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2011</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

